Prognostic factors in stage-i (T1N0) breast carcinoma patients: who needs adjuvant systemic treatment?
There is no consensus about the need of adjuvant therapy in T(1)N(0) breast carcinoma patients. To select a subgroup of these patients who may benefit from adjuvant systemic therapy, prognostic factor analyses were carried out using chi-square test and Cox regression analysis in 187 patients data in this retrospective study. Primary endpoint was distant metastasis (DM). The multivariate Cox analysis showed that age group (<or=35 years vs >35 years, p=0.01; Hazard Ratio [HR], 15.4; 95% Confidence Interval [CI], 1.8-133.0), tumor size (>1 cm vs <or=1 cm, p=0.002; HR,3.5; CI:1.2-13.4) and LVI (yes vs no, p=0.002; HR,34.7; CI:3.6-326.0) were strongly associated with DM. From this analysis, a risk estimation model for DM was constructed. Whereas patients at low risk had a 96% distant metastasis-free survival, this rate for those at high risk had a 37% (p<0.00001). According to the proposed model including age, tumor size and LVI, the patients at high risk might benefit from adjuvant systemic therapy.